trending Market Intelligence /marketintelligence/en/news-insights/trending/oX8layS1J1QhAbSHguZzDw2 content esgSubNav
In This List

Motif Bio plans placing to fund development of novel antibiotic

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Motif Bio plans placing to fund development of novel antibiotic

Motif Bio PLC said it plans to raise about £19.4 million via a conditional placing to fund the development of iclaprim, its novel antibiotic candidate.

The company will issue new ordinary shares for the placing, which will be conducted through an accelerated bookbuild exercise. The placing is subject to approval of certain resolutions by company shareholders.

A portion of the proceeds will also be used for general corporate purposes.

Peel Hunt LLP is acting as book runner for the placing and nominated adviser to the company, while Northland Capital Partners Ltd. is acting as co-lead manager.